We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

今年1月中旬，这家生产减肥药物Zepbound的制造商下调了第四季度的收入预期，原因是其GLP-1药物的销售增速低于预期。这一警告紧随10月份令人失望的第三季度业绩之后，导致其股价在几个月内表现波动。自年初以来，Eli Lilly股价试图重拾动力，上涨了9%。然而，周二收盘时，其股价较去年8月底创下的52周高点972.53美元仍低15%。当时，许多人认为该公司有望达到1万亿美元的估值。

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...

周三，Truist Securities重申了对Eli Lilly and Company (NYSE: LLY ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...